Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.


Journal

Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 09 09 2018
revised: 07 04 2019
accepted: 08 04 2019
pubmed: 13 4 2019
medline: 30 7 2019
entrez: 13 4 2019
Statut: ppublish

Résumé

Pseudomonas aeruginosa is a notorious pathogen with increasing multi-drug resistance. This situation makes it urgent to develop a prophylactic vaccine against this pathogen. Different virulence factors play a crucial role in P. aeruginosa infection. This study focused on evaluation of the iron acquisition protein HitA as a potential vaccine candidate against P. aeruginosa in a murine infection model. The recombinant ferric iron-binding periplasmic protein HitA was overexpressed in Escherichia coli and was purified using metal affinity chromatography. The purified antigen was administered to mice in combination with Bacillus Calmette-Guérin (BCG) as an adjuvant using different vaccination regimens. Serum samples were tested for IgG1, IgG2a and total IgG antibody responses which were extremely significant. Following challenge of mice with P. aeruginosa, there was a significant reduction in bacterial load in lungs of immunized mice compared to negative control mice. Opsonophagocytic assay supported the previous results. In addition, histopathological examination of livers of challenged mice showed a significant improvement difference between immunized mice and negative control mice in various histopathological parameters. Up to our knowledge, this is the first report that investigates HitA as a potential vaccine antigen. Overall, the results of this study demonstrate the protective effect of HitA recombinant protein and highlight its importance as a promising vaccine candidate against P. aeruginosa infection.

Identifiants

pubmed: 30978430
pii: S0882-4010(18)31560-2
doi: 10.1016/j.micpath.2019.04.014
pii:
doi:

Substances chimiques

Adjuvants, Immunologic 0
Antibodies, Bacterial 0
Bacterial Vaccines 0
Immunoglobulin G 0
Periplasmic Proteins 0
Recombinant Proteins 0
Vaccines, Synthetic 0
Iron E1UOL152H7

Types de publication

Journal Article

Langues

eng

Pagination

181-185

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Mona A Elhosary (MA)

Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Mohammed Bahey-El-Din (M)

Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address: m.bahey-el-din@alexu.edu.eg.

Amany AbdelBary (A)

Department of Pathology, Faculty of Medicine, Alexandria University, Egypt.

Nadia El Guink (N)

Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Hamida M Aboushleib (HM)

Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH